doi: 10.1136/gutjnl-2020-323617 91 NicolucciA.CharbonnelB.GomesM
It therefore makes more sense to group them by drug class where the evidence is solid
The approval was backed by the Phase II open-label AGAVE-201 trial, where treatment with a 0.3-mg/kg dose of Niktimvo elicited an overall response rate of 75%, with a median time to response of 1.5 months
In addition, other patient-specific treatment strategies tailoring the use of GLP-1 RAs and other options to the HF phenotype and stage are likely also valuable to study and validate
Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety
Welcoming New Longevity Docs Longevity Docs unites board-certified physicians from diverse specialties - including cardiology, endocrinology, surgery, psychiatry, public health, regenerative, and functional medicine - across private practice, academia, and health systems worldwide